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It  is well established that  the  hemagglutinin  (HA)  1 molecule of influenza virus is 
highly variable and frequently exhibits antigenic changes  (1-3).  In nature the sponta- 
neously  arising mutants  are  likely to  be  overgrown  by the  parent  virus,  unless  the 
mutation provides the variant with a  selective growth advantage, such as the ability to 
replicate in the presence of antibodies that neutralize the parental virus strain. This is 
thought to be the basis of the minor antigenic changes (drift) that occur continuously in 
nature  in a  partially immune  host population during interpandemic periods and that 
sporadically lead to new epidemic virus strains.  Experimental support for this mecha- 
nism of antigenic drift has been obtained in many previous studies in which antigenic 
variants have been shown to emerge if influenza virus is grown, in vivo or in vitro, in the 
presence of subneutralizing doses of anti-viral antiserum (4-8). Antigenic drift, however, 
is still little understood at the molecular level. It is not known, for example, whether a 
single amino acid substitution in the antigenic site of the HA is sufficient to cause a 
detectable  antigenic  drift  or,  as  suggested by  Fazekas de  St.  Groth  (9),  to  induce  a 
transition from an existing to a subsequent epidemic virus strain. 
In the present study,  antigenic variants were  selected from a  cloned preparation of 
PR8 virus by means of a monoclonal hybridoma antibody (10).  Under these experimental 
conditions,  variant  viruses could be  selected  in  a  single egg  passage.  The  antigenic 
changes exhibited by these naturally occurring mutants were delineated by means of 
monoclonal antibodies. 
Materials and Methods 
Viruses.  The influenza virus PR8 (A/PR/8/34  [HON1]) was grown in embryonated eggs and 
the infectious allantoic fluid was used as parental virus for the selection of variants. In addition, 
the following influenza A viruses were used in the radioimmunoassay (RIA) for the determination 
of the specificity of anti-viral antibodies: SW (A/Swine/31 [HswN1]);  WSE (A/WSE/33 [HON1]); 
WSN  (A/WSN/33 [HON1]); BH  (A/BH/35  [HON1]); MEL  (A]Melbourne/35  [HON1]); HICK  (A/ 
Hickcox/40 [HON1]); BEL (A/Bellamy/42 [HON1]); WEISS (A/Weiss/43 [HON1]); CAM (A/CAM/46 
[H1N1]); FM1 (A/FM/1/47 [H1N1]); recombinant viruses: Eq-PR8 (A/equine/Miami/l/63 [Heq2]- 
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A]PR/8/34 [N1]); and JAP-BEL (AJJapan/305/57  [H2]-A/Bellamy/42  [N1]). All viruses were grown 
in the allantoic cavity of 10-day-old embryonated hen's eggs and were purified by adsorption to 
and  elution  from  human  erythrocytes  and  by  banding  in  a  sucrose  gradient  as  described 
previously (11). 
Monoclonal Anti-HA Antibodies.  The moneclonal anti-HA(PR8)  antibody  produced  by the 
hybridoma PEG-1  (subsequently referred to as PEG-I) has been described in detail elsewhere 
(10). Clone 6 of the hybridoma mass culture was used. The hybridoma was grown in ascitic form 
in  the  peritoneal cavity of BALB/c mice  (Charles  River Breeding Laboratories,  Wilmington, 
Mass.)  pretreatod by an i.p. injection of 0.5 ml pristane (Aldrich Chemical Co., Inc., Milwaukee, 
Wis.). 
Secondary monoclonal anti-HA(PRS) antibodies were produced in the splenic fragment culture 
system according to published methods (11, 12). The antibodies used in the present study were 
derived from  splenic fragment  cultures  obtained  after  adoptive transfer  of spleen cells from 
BALB/c mice primed 4-6 mo previously by an i.p. injection of 1250 HA U of PRS. The specificity of 
the  monoclonal antibodies was determined by means of the RIA:  an  antibody was considered 
specific if it bound to PR8(HON1) but not to the hybrid viruses Eq-PR8 (Heq2N1)  and JAP-BEL 
(H2N1) (12). 
Antisera.  Hyperimmune antisera to isolated HA(PR8)  subunits and to intact viruses were 
prepared in rabbits and in goats (13, 14). 
Serological  Tests.  RIA  was  performed  as  described  previously  (12) except  for  the  viral 
immunoadsorbent  (IAds) which was prepared according to the method of Rosenthal et al.  (15). 
Briefly, the purified virus (roughly 25 HA U) in 25 ~1 Dulbecco's phosphate-buffered saline was 
added to individual wells of round bottom polyvinyl plates  (Cooke  Laboratory Products  Div., 
Dynatech Laboratories Inc., Alexandria, Va.). The virus sample was dried overnight and fixed for 
5 min with methanol at room temperature, then residual methanol was rinsed off. 15-~1 replicate 
samples containing 2.5-5 ng of monoclonal antibody were added to each well and incubated for 90 
min at room temperature. The wells were washed three times and the amount of antibody bound 
to the various IAds was quantitated by means of 12SI-labeled rabbit anti-mouse F(ab')2  or goat 
antisera (Meloy Laboratories Inc.,  Springfield, Va.) specific  for the predominant isotype of the 
given monoclonal antibody. The reactivity type (RT) was determined as follows (12): the amount 
of antibody in the test sample that bound to the parental virus PR8 was defined as 100%. Positive 
binding indicates that greater than or equal to 10% of the antibody in the test sample bound to 
variant or heterologous virus; negative binding indicates that less than 10% was bound.  Each 
assay was performed in duplicate. 
HA titrations and hemagglutinin-inhibition (HI) tests were done as previously described (16). 
The antisera were treated with receptor-destroying enzyme and the dilutions of antiserum were 
allowed to interact with antigen for 60 min at 20°C before the addition of chicken erythrocytes. 
Virus  neutralization tests  were  performed  in  embryonated  eggs as  outlined below for the 
selection of variants  except that  50  egg infective doses  of virus were incubated  with  various 
dilutions of anti-viral antibodies. 
Selection of Virus Variants.  0.5-ml dilutions of PEG-1 ascitic fluid were mixed with undiluted 
A/PR8 virus (0.05 ml high infectivity allantoic fluid) and incubated at 20°C for 30 min. The virus- 
antibody mixtures were injected into groups of 10 embryonated hen's eggs (11 days) and incubated 
at 35°C for 2 days. The inoculated eggs were harvested individually and tested for the presence of 
influenza virus by  HA titration.  The virus yields from the individual eggs were tested in HI 
assays with the monoclonal antibody preparation to AJPR8; those viruses that were inhibited 10- 
fold less efficiently or were not inhibited at all by the monoclonal antibody preparation were 
cloned twice at limiting dilution in embryonated hen's eggs. 
Results 
Selection  of PR8-Variants  with  Monoclonal Antibodies  Produced  by PEG- 
1.  A  cloned  parental  PR8  virus  preparation  was  made  by  two  consecutive 
growth  passages  of PR8  at  limit  dilution  in  embryonated  hen's  eggs  in  the 
absence  of anti-viral antibodies.  As shown in Table I,  PEG-1  was effective at 
inhibiting hemagglutination  by  and  infectivity of the parental  virus prepara- 
tion. W.  GERHARD  AND  R. G.  WEBSTER 
TABLE  I 
Interaction of Parent and Variant Viruses with PEG-1 
385 
Neutralization of  RIA ng  Antibody bind-  Virus  HI titer  (log  2)  infectivity  (log  2)  ing 
PR8 (Parent)  7.87  14.33  65 
PR8-V2  <3.0  <5.95  <0.1 
PRS-V3  <3.0  9.27  (-5.06)  0.9 (-6.20) 
PRS-V4  <3.0  8.27  (-6.06)  1.0 (-6.04) 
PR8-V6  <3.0  10.64 (-3.69)  2.8 (-4.55) 
PR8-V7  <3.0  <5.32  <0.1 
PRS-V8  <3.0  <5.32  <0.1 
PR8-V9  <3.0  <5.32  <0.1 
PEG-I antibody was assayed in neutralization test,  HI test,  and RIA for interaction  with the 
indicated  viruses.  The  tests were performed as  (mtlined in  Materials and Methods. Neutralization 
and HI titer  refer  to undiluted PEG-1 ascitic  fluid.  The concentration of  antibody determined in 
the  RIA refers  to  a 15-~I  sample  of  PEG-1 diluted  1/250.  Entries in  parentheses: log  2 (heterologous 
interaction)-log  2 (homologous interaction). 
Virus harvested individually from eight eggs after incubation of the parental 
PR8 virus inoculum with undiluted PEG-1 ascitic fluid was cloned twice at limit 
dilution in embryonated eggs in the absence of PEG-1. These virus preparations 
were designated PRS-V2 through PRS-V9 (V, variant).  PR8-V5 was not used in 
these experiments.  Compared to the parental  PRS, these viruses exhibited no 
detectable or a  much smaller reactivity with PEG-1 in HI test,  neutralization 
test,  and RIA,  thus indicating  that they represented variants  of the parental 
PR8 (Table I). 
Antigenic Relationship between Parental Virus and Variants.  An antigenic 
comparison between parental  PR8 virus and its variants was done in HI tests 
using several antisera  raised in vivo against the parental  virus (Table II).  In 
contrast to PEG-1  (Table I),  these antisera  cross-reacted extensively with all 
variants and, thus, could not provide clear-cut evidence for antigenic differences 
between variants  and parental  virus.  Similarly,  the antisera  to variants  2,  3, 
and 4, respectively, were unable to distinguish the homologous variant from the 
parental virus or from the other variants. 
Taken  together,  the  data  of Tables I  and  II  indicate  that  differences exist 
among these viruses, but they are probably recognized only by a small fraction 
of the  anti-viral  antibodies present  in the heterogeneous antisera.  Therefore, 
the  antigenic  relationship  between parental  and  variant  viruses was further 
delineated by means of monoclonal anti-HA antibodies produced in vitro in the 
splenic  fragment  system.  Due to  the  relatively  small  quantities  of antibody 
available,  this  analysis  could  be  performed  only  in  the  RIA.  The  RT  of a 
monoclonal antibody in the RIA was determined as described in Materials and 
Methods. 
As  shown  in  Table  III,  81  of the  95  randomly  selected  monoclonal  anti- 
HA(PR8 parent) antibodies reacted in the RIA with all variants.  14 antibodies 
provided  evidence  for  antigenic  differences  between  the  HA  of parent  and 
variant viruses: 11 of the 14 delineated a determinant present on the HA of all 
viruses except V3 and V4; two antibodies delineated a determinant present only 
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TABLE  II 
Antigenic Relationship between Parental and Variant Influenza Viruses in HI Tests 
Virus 
Goat-  Rabbit-  BALB/c-  Murine-  Rabbit-  Rabbit-  Rabbit- 
anti* PR8  anti* PR8  anti§  PR8  antill  PR8  anti¶  anti¶  anti¶ 
parent  parent  parent  parent  variant 2  variant 3  variant 4 
(isolated  (isolated  (whole  (whole  (whole  (whole  (whole 
HA)  HA)  virus)  virus)  virus)  virus)  virus) 
PR8 Parent  13.55  14.92  12.87  12.37  13.55  14.21  14.21 
PR8-V2  14.55  15.61  11.87  12.47  14.61  15.52  15.52 
PRS-V3  13.29  14.36  12.82  12.37  13.29  14.14  14.43 
PRS-V4  13.29  14.43  11.87  12.62  13.29  14.14  14.21 
PR8-V6  13.43  14.55  12.27  12.67  13.55  13.87  14.05 
PRS-V7  14.14  15.52  11.27  12.27  14.55  15.14  15.01 
PR8-V8  13.67  15.32  11.67  12.17  13.67  14.61  14.61 
PRS-V9  13.29  15.21  12.02  12.07  14.14  14.21  14.21 
Figure gives  the  reciprocal  of  the  dilution  inhibiting  three out  of  four  hemagglutinating doses of 
the  above viruses. 
* Hyperimmune goat  antisera to  the isolated  HA molecule. 
* Hyperimmune rabbit  antisera  to  the isolated  HA molecule. 
§ Pooled serum from BALB/c mice obtained 8 days after  first  bodst  with PR8 parental virus. 
II Pooled serum from DBA, C57BL/10, and A  mice obtained 8 days after first  boost with PR8 
parental virus. 
¶ Hyperimmune rabbit  antisera  to  intact  purified  virus. 
TABLE  HI 
Comparison between Parental Virus and Variants by Means of Monoclonal Antibodies 
in the RIA 
RT exhibited in RIA* 
Number of  anti-  PR8 
body clones  Parent 




of  dis- 
V9  tinct 
clono- 
types$ 
81§  +  +  +  +  +  +  +  +  46 
11§  +  +  -  -  +  +  +  +  7 
2§  +  -  +  +  +  -  -  -  1 
1§  +  -  -  -  +  -  -  -  1 
(PEG-l, cl 611)  +  .......  1 
* Antibodies were tested  for binding to indicated viruses in the RIA. Negative (-) reactivity 
indicates  that less  than 10% of  the  antibody in  the  test  sample bound to  the  given  virus.  See also 
Materials and Methods for  the  definition  of  the RT. 
Number of  antibodies  that could be  further  distinguished on  the basis  of  their  interaction  in  the 
RIA with the influenza viruses SW, WSN, WSE, BH, MEL, HICK, WEISS, BEL, CAM, and 
FM1. 
§ Anti-HA (PRS) antibody clones  produced in  the splenic  fragment system. 
I[  Hybridoma antibody used for  selection  of  variant viruses. 
on  the  parent  and  V6.  Furthermore,  a  unique  determinant  of the  parent  HA 
was detected by the PEG-1  antibody. 
Since  all  antibodies  that  expressed  a  given  RT  could  represent  a  single 
clonotype, i.e., a  single species of antibody  combining  sites, the mere  number  of 
antibody  clones exhibiting  any  given  RT  cannot  provide,  per  be,  a  measure  of W.  GERHARD  AND  R.  G.  WEBSTER  387 
the extent of antigenic relatedness. Thus, to estimate the minimum number of 
different antibody combining sites included in the analysis, all antibodies were 
further tested for their reaction with the following 10 heterologous viruses: SW, 
WSN,  WSE,  BH, MEL,  HICK,  WEISS,  BEL,  CAM,  and  FM1.  This  analysis 
indicated that the 81 antibodies that cross-reacted with all variants comprised a 
minimum of 46 different clonotypes, each characterized by a  unique pattern of 
reaction with the panel of the above mentioned heterologous viruses (Table III, 
last column).  Thus,  under the experimental  conditions of the RIA, at least 46 
distinct antibody combining sites were unable to recognize a difference between 
the  HA of parental  virus  and  that  of its  variants.  Similarly,  at  least  seven 
clonotypes delineated the determinant present on the HA of all viruses except 
V3 and V4. In contrast,  the other three determinants  seemed to be recognized 
by only a single clonotype. 
The Ability of Strain-Specific  and Cross-Reactive Antibodies  to Recognize 
the Antigenic Change on the Variants.  Two major groups of antigenic deter- 
minants  can  be distinguished,  operationally,  on the  viral  HA:  determinants 
that are characteristic for a given virus strain (strain-specific) and determinants 
that  are shared by two or more virus strains  (common)  (12,  17-20).  Recently, 
Laver  et  al.  (17)  speculated  that  the  two  groups  of determinants  might  be 
subject to independent antigenic variation.  In the present study, PR8 variants 
were selected on the basis of an antigenic change that decreased their reactivity 
with  PEG-l,  an  antibody  that  is  directed  against  a  strain-specific  HA(PRS) 
determinant.  Thus, if the above hypothesis were correct, the antigenic change 
on the PR8 variant would be recognized exclusively by antibodies to the strain- 
specific determinants  but not by antibodies to the common determinants.  The 
splenic antibodies were, therefore, grouped with regard to the HA determinant 
recognized; antibodies that did not cross-react with any of the 10 heterologous 
viruses included in the analysis were assumed to be directed against one of the 
PR8  strain-specific  determinants.  Antibodies  to  common  determinants  (i.e., 
those shared  in a  cross-reactive form by PR8 and one or several heterologous 
viruses) were further  subdivided into slightly cross-reactive  (those that cross- 
reacted in the RIA with PR8 and three heterologous viruses) and highly cross- 
reactive  (those that  cross-reacted in the RIA with  PR8 and  more than  three 
heterologous viruses) antibodies. 
The results of this analysis are in partial agreement with the above hypothe- 
sis (Table IV). Thus, 41% of the strain-specific antibodies but none of the highly 
cross-reactive  antibodies  recognized  the  antigenic  change  on  the  variants. 
However, some slightly cross-reactive antibodies were also able to delineate the 
antigenic change, though less frequently than strain-specific antibodies. 
Antigenic Relationship between Variants and Standard Virus Strains of the 
AO Subtype.  The  analysis  described in  the  previous section  of all  antibody 
clones for their  reactivity to heterologous viruses of the A0 and  A1 subtypes 
could  shed  some  light  on  the  question  of whether  the  antigenic  drift  that 
occurred  in  the  PR8  variants  was  in  the  direction  of existing  laboratory- 
maintained virus strains. Complete or partial correlation of the reactivity of the 
various  antibodies  with  a  variant  and  a  heterelogous  virus  would  indicate 
identity with or drift in the direction of the given virus strain. 
Table  V  shows that  roughly  50%  of the  monoclonal  antibody  preparations 388  ANTIGENIC  DRIFT  IN  INFLUENZA  VIRUSES 
TABLE  IV 
Relationship between Cross-Reactivity of Monoclonal 
Antibodies and Recognition of  Antigenic Change on PR8 
Variants 
Number of antibodies 
Reactivity  of  antibodies* (number of  Recognizing anti- 
cross-reacting  heterologous viruses)  Total  genic change on 
variants 
HA(PR8)-Specific  17  7 (41%) 
Slightly  cress-reactive  (I-3)  35  7 (20%) 
Highly cross-reactive (4-10)  43  0 
* The reactivity  of  the  splenic  monoclonal antibodies  was based on  their 
interaction  in the RIA with PR8, SW, WSN, WSE, BH, MEL, HICK, 
WEISS,  BEL, CAM,  and FM1  (Table Ill legend). HA(PR8)-specific 
antibodies  reacted exclusively  with PR8. Slightly  cross-reactive  anti- 
bodies reacted with PR8 and 1-3 heterologous viruses;  highly cross- 
reactive  antibodies reacted with PR8 and 4-10 heterologous viruses. 
TABLE V 
Relationship  between Reactivity of Antibody Clones with 
Heterologous Virus Strains 
Variants and Reactivity with 
Splenic  antibodies  Antibodies reacting  in RIA with: 
included in  analy- 
sis  V2*  V3*  V6*  WSE  BH  MEL  HICK  WEISS  BEL 
955  92  83  95  46  49  45  31  43  26 
(98%)  (87%) (100%)  (48%)  (52%)  (47%)  (33%)  (45%)  (27%) 
71§  E  41.9  44.6  41.0  28.2  39.1  23.7 
0:  46  48  42  29  43  23 
* v2 represents  V2, V7, v8, and V9; V3 represents  V3 and V4. The splenic antibodies could not 
further differentiate the variants within each group under the conditions of the RIA. 
5 The 95 splenic antibodies include those that react exclusively with PR8 and those that crossreact 
in the RIA with a heterologous virus strain. 
§ 71  splenic antibodies that react  with  PR8-V3 and  one or several  heterologous viruses.  The 
expected number (E) of clones reacting with the indicated heterologous virus is calculated from 
the  total  number  of cross-reacting  clones assuming  that  there  is  no  correlation  between 
reactivity  with V3 and a heterologous virus.  0 = observed number of clones reacting with V3 
and indicated heterologous virus. 
cross-reacted in the RIA with WSE, BH, MEL, or WEISS. On the other hand, 
the least cross-reactive of the PR8 variants  (V3,  V4) reacted with 87% and the 
most cross-reactive (V6) with 100% of the splenic antibodies. This indicated that 
all  variants  remained  antigenically very closely related  to the  PR8  parental 
virus.  Some drift toward the antigenicity of WSE,  BH,  and WEISS may have 
occurred in V3 and V4 since antibodies reacting with the latter variants reacted 
slightly more often than expected with WSE,  BH,  and WEISS.  However, the 
difference was not significant in the )~2 test. 
Discussion 
Influenza virus can produce many different types of variants (21).  Two types 
of variation in the  HA molecule may provide a  mutant virus with a  selective W.  GERHARD  AND  R.  G.  WEBSTER  389 
growth advantage over the parental virus if the selection of variants is based on 
the neutralization of the parent virus by anti-HA antibodies. A mutation may 
occur that leaves the antigenicity of the HA unchanged but increase its avidity 
for the receptors of the host cell (22). Consequently, antibodies would exhibit a 
decreased activity against such adsorptive mutants in assays where antibodies 
have  to  compete with the  binding of the  virus  to  cell  receptors  as  in  the 
neutralization  or  the  HI  test.  Antigenic  analyses  performed  in  the  RIA, 
however,  are  virtually independent of this  type of variation except for the 
possibility that an adsorptive mutation would lead to a considerable underesti- 
mation of the virus concentration used in the RIA (which is based on the HA 
titer of the virus). However, it does not seem possible that the variants used in 
the present study are adsorptive mutants since the various viral immunoadsorb- 
ents were able to bind equal amounts of most antibodies tested. Therefore, since 
each type of cross-reaction exhibited by a  monoclonal antibody in  the  RIA 
defines a  distinct group of antigenic determinants, each novel type of cross- 
reaction, thus, delineates a distinct antigenic mutation. 
Analysis of the seven viruses (V2, V3,  V4,  V6,  V7,  V8,  V9)  selected with 
PEG-1  showed that all represented antigenic variants of the parental virus. 
Furthermore, the seven variants exhibited three distinct antigenic changes, one 
exemplified by the variant group, V2, V7, VS, and vg, one by the group V3 and 
V4,  and one by V6.  This is obviously a  minimum estimate of the number of 
distinct antigenic mutations expressed by the variants, since some additional 
antigenic differences among the variants might have escaped detection as a 
result of the limited number of antibodies included in the analysis. Further- 
more, the RIA as performed and scored in the present study cannot provide an 
accurate  measure of the  affinity of each variant-antibody interaction  (12). 
Notion of the latter would be required, however, to prove unequivocally the 
identity of a given antigenic change expressed on the variants. 
Antigenic differences between the  variants  and  the  parental  virus  were 
minimal. For instance, only 12 of the 95 monoclonal splenic antibodies were 
able to detect the antigenic change exhibited by V3 and V4 in the RIA and only 
PEG-1  recognized the variation exhibited by V6.  These findings are further 
corroborated by the  fact that  heterogeneous anti-HA  antisera  could hardly 
discriminate between the variants and the parental virus. This suggests that 
none of the mutations,  although they must have resulted from at least one 
amino acid substitution, would have been epidemiologically relevant, i.e., none 
of the variants would have escaped rapid neutralization in a host population 
with  pre-existing  immunity to  the  parental  virus.  This  conclusion  is  also 
supported by results of the comparison of the variants with formerly epidemic 
virus strains of the A0  subtype: all variants were antigenically much more 
closely related to PR8 (year of original isolation, 1934) than to BH (1935), MEL 
(1935) or any of the later isolates of the HON1 era. 
Antigenic drift from an existing strain to a future epidemic virus strain thus 
seems to require several amino acid substitutions.  This idea agrees with the 
observation of Laver et al.  (17) who demonstrated multiple differences in the 
peptide maps of the HA of epidemic strains isolated in 1968 and 1972, respec- 
tively.  However,  neither  the  number  nor  the  location  of the  amino  acid 
substitutions was determined in these studies, and it is not known whether all 390  ANTIGENIC  DRIFT  IN  INFLUENZA  VIRUSES 
substitutions were in the antigenic sites. The present observations are obviously 
incompatible with the assumption made by Fazekas de St. Groth (9) that each 
epidemic strain within a subtype is derived from the preceding epidemic virus 
strain  by a  single amino acid substitution in  the antigenic area of the HA 
molecule. Although the possibility has not yet been eliminated, it seems rather 
unlikely that the degree of variation observed in the PEG-1 epitepe of the HA 
differs fundamentally  from the variation of other HA determinants. 
It has been estimated by means of monoclonal anti-HA antibodies of murine 
origin that the antigenic site of the HA is composed of approximately 15-60 
individual determinants (23), some of which are strain-specific and others of 
which are shared by the HA of two or more virus strains.  Given the electron 
microscopic observation that anti-HA antibodies interact only with a part of the 
hydrophilic portion of the HA molecule (24) measuring roughly 50  × 50/k and 
given that the size of an antibody combining site is 15  x  20/k (25), one must 
assume that many of the determinants represent overlapping protein struc- 
tures. This notion is supported by the observation that not only strain-specific 
but also  some cross-reactive antibodies were able to recognize the antigenic 
changes in the strain-specific PEG-1 epitope. On the other hand, none of the 43 
antibodies that cross-reacted with more than three heterologous viruses could 
recognize the antigenic changes in the PEG-1  epitope. This indicates that the 
strain-specific determinants can vary independently of the highly cross-reactive 
(common) determinants (17). Thus, the area of complementarity of the highly 
cross-reactive antibody  combining sites  does  not  comprise the  PR8  strain- 
specific determinants. The present observation does not, however, exclude the 
possibility that the area of complementarity of the combining site of strain- 
specific  antibodies comprises both  strain-specific and cross-reactive determi- 
nants, and therefore, does not allow us to conclude that the strain-specific and 
common determinants are separate entities. The latter could be proven by the 
demonstration of noncompetitive binding of specific  and cross-reactive hybri- 
doma antibodies to the same HA molecule under saturating conditions or by the 
demonstration that  variants  selected with  cross-reactive antibodies  are  not 
recognized by strain-specific antibodies. 
The present study selected PR8 variants only on the basis of mutations that 
modified (among others) the PEG-1  epitope of the parental HA molecule. It 
remains to be seen whether the same degree of variability also occurs in other 
HA determinants. This is currently being investigated using anti-HA hybri- 
doma antibodies with other reactivities for selection of variants. It is anticipated 
that this type of analysis will ultimately provide an estimate of the repertoire of 
antigenic changes available to a given virus strain such as PR8. Furthermore, 
it may allow us to accurately trace phylogenetic relationships between virus 
strains within a subtype through selection of several generations of consecutive 
variants.  And finally,  it  is  likely that  a  panel  of antigenic variants whose 
primary HA structures differ only by amino acid substitutions related to the 
antigenic site, may be very useful, in conjunction with amino acid sequencing, 
in the analysis of the molecular structure of the antigenic area of the HA. 
Summary 
Antigenic variants of A/PR/8/34  [HON1] influenza virus were selected after a W.  GERHARD  AND  R.  G.  WEBSTER  391 
single passage of the parent virus in embryonated chicken eggs in the presence 
of  monoclonal antibodies to this virus. The monoclonal antibodies were produced 
by a  hybridoma and  were  specific for an  antigenic determinant on the  HA 
molecule of the parent virus.  Seven antigenic variants were analyzed with 95 
monoclonal anti-HA antibodies prepared in vitro in the splenic fragment culture 
system. 
Three  subgroups  of antigenic  variants  were  distinguished.  The  antigenic 
changes  were  primarily recognized by  monoclonal antibodies  to  the  strain- 
specific determinants of  the parental hemagglutinin (HA) molecule. Monoclonal 
antibodies to HA determinants shared (in an identical or cross-reactive form) 
by parental virus and more than three heterologous viruses of the HON1 and 
H1N1 subtypes were unable to recognize the antigenic change on the variants. 
Similarly, heterogeneous antibody preparations could not differentiate between 
parental and variant viruses. 
The results are compatible with the idea that the HA of PR8 has available a 
large repertoire of antigenic modifications that may result from single amino 
acid substitutions, and that antigenic changes can occur in the strain-specific 
determinants on the HA molecule in the absence of concomitant changes in the 
cross-reactive HA determinants. The findings suggest that antigenic drift, in 
order to be epidemiologically significant, probably requires a  series of amino 
acid substitutions in, or close to, the antigenic area on the HA molecule. 
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